BACKGROUND: Heart failure (HF) care constitutes an increasing economic burden on the health care system, and has become a key focus in the health care debate. However, there are limited data on the lifetime health care costs for individuals with HF after initial diagnosis. METHODS AND RESULTS: Olmsted County residents with incident HF from 1987 to 2006 were identified. Direct medical costs incurred from the time of HF diagnosis until death or last follow-up were obtained using population-based administrative data through 2007. Costs were inflated to 2008 US dollars using the general Consumer Price Index. Inpatient, outpatient, and total costs were estimated using a 2-part model with adjustment for right censoring of data. Predictors of total costs were examined using a similar model. A total of 1054 incident HF patients were identified (mean age, 76.8 years; 46.1% men). After a mean follow-up of 4.6 years, 765 (72.6%) patients had died. The estimated total lifetime costs were $109 541 (95% confidence interval, $100 335 to 118 946) per person, with the majority accumulated during hospitalizations (mean, $83 980 per person). After adjustment for age, year of diagnosis, and comorbidity, diabetes mellitus and preserved ejection fraction (≥50%) were associated with 24.8% (P=0.003) and 23.6% (P=0.041) higher lifetime costs, respectively. Higher costs were observed at initial HF diagnosis and in the months immediately before death in those surviving >12 months after diagnosis. CONCLUSIONS: HF imposes a significant economic burden, primarily related to hospitalizations. Variations in cost over a lifetime can help identify strategies for efficient management of patients, particularly at the end of life.
BACKGROUND:Heart failure (HF) care constitutes an increasing economic burden on the health care system, and has become a key focus in the health care debate. However, there are limited data on the lifetime health care costs for individuals with HF after initial diagnosis. METHODS AND RESULTS: Olmsted County residents with incident HF from 1987 to 2006 were identified. Direct medical costs incurred from the time of HF diagnosis until death or last follow-up were obtained using population-based administrative data through 2007. Costs were inflated to 2008 US dollars using the general Consumer Price Index. Inpatient, outpatient, and total costs were estimated using a 2-part model with adjustment for right censoring of data. Predictors of total costs were examined using a similar model. A total of 1054 incident HF patients were identified (mean age, 76.8 years; 46.1% men). After a mean follow-up of 4.6 years, 765 (72.6%) patients had died. The estimated total lifetime costs were $109 541 (95% confidence interval, $100 335 to 118 946) per person, with the majority accumulated during hospitalizations (mean, $83 980 per person). After adjustment for age, year of diagnosis, and comorbidity, diabetes mellitus and preserved ejection fraction (≥50%) were associated with 24.8% (P=0.003) and 23.6% (P=0.041) higher lifetime costs, respectively. Higher costs were observed at initial HF diagnosis and in the months immediately before death in those surviving >12 months after diagnosis. CONCLUSIONS: HF imposes a significant economic burden, primarily related to hospitalizations. Variations in cost over a lifetime can help identify strategies for efficient management of patients, particularly at the end of life.
Authors: J R Lave; C L Pashos; G F Anderson; D Brailer; T Bubolz; D Conrad; D A Freund; S H Fox; E Keeler; J Lipscomb Journal: Med Care Date: 1994-07 Impact factor: 2.983
Authors: Véronique L Roger; Susan A Weston; Margaret M Redfield; Jens P Hellermann-Homan; Jill Killian; Barbara P Yawn; Steven J Jacobsen Journal: JAMA Date: 2004-07-21 Impact factor: 56.272
Authors: Véronique L Roger; Jill Killian; Mary Henkel; Susan A Weston; Tauqir Y Goraya; Barbara P Yawn; Thomas E Kottke; Robert L Frye; Steven J Jacobsen Journal: J Clin Epidemiol Date: 2002-06 Impact factor: 6.437
Authors: Yariv Gerber; Susan A Weston; Cecilia Berardi; Sheila M McNallan; Ruoxiang Jiang; Margaret M Redfield; Véronique L Roger Journal: Am J Epidemiol Date: 2013-08-29 Impact factor: 4.897
Authors: Shannon M Dunlay; Margaret M Redfield; Ruoxiang Jiang; Susan A Weston; Véronique L Roger Journal: Circ Heart Fail Date: 2015-04-01 Impact factor: 8.790
Authors: Susan J Pressler; Alison Martineau; Judith Grossi; Bruno Giordani; Todd M Koelling; David L Ronis; Penny L Riley; Cheng-Chen Chou; Barbara J Sullivan; Dean G Smith Journal: Heart Lung Date: 2013-07-01 Impact factor: 2.210